Nucleus Software Exports Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Nucleus Software Exports wird ein jährliches Gewinn- und Umsatzwachstum von 18.1% bzw. 15.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 18.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 26.7% betragen.
Wichtige Informationen
18.3%
Wachstumsrate der Gewinne
18.3%
EPS-Wachstumsrate
Software Gewinnwachstum | 15.8% |
Wachstumsrate der Einnahmen | 12.5% |
Zukünftige Eigenkapitalrendite | 25.6% |
Analystenabdeckung | Low |
Zuletzt aktualisiert | 05 Jul 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Nucleus Software Exports Limited (NSE:NUCLEUS) Held Back By Insufficient Growth Even After Shares Climb 26%
Jul 05Nucleus Software Exports' (NSE:NUCLEUS) Earnings Are Of Questionable Quality
Jun 29Nucleus Software Exports' (NSE:NUCLEUS) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 22Estimating The Fair Value Of Nucleus Software Exports Limited (NSE:NUCLEUS)
Apr 04Nucleus Software Exports (NSE:NUCLEUS) Could Become A Multi-Bagger
Mar 15Nucleus Software Exports Limited (NSE:NUCLEUS) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Feb 21Why Investors Shouldn't Be Surprised By Nucleus Software Exports Limited's (NSE:NUCLEUS) Low P/E
Dec 19Nucleus Software Exports' (NSE:NUCLEUS) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 23The Return Trends At Nucleus Software Exports (NSE:NUCLEUS) Look Promising
May 27Nucleus Software Exports (NSE:NUCLEUS) Could Be Struggling To Allocate Capital
Feb 15Returns On Capital Are Showing Encouraging Signs At Nucleus Software Exports (NSE:NUCLEUS)
May 19Returns On Capital At Nucleus Software Exports (NSE:NUCLEUS) Have Hit The Brakes
Nov 29The Return Trends At Nucleus Software Exports (NSE:NUCLEUS) Look Promising
Aug 13Should You Be Adding Nucleus Software Exports (NSE:NUCLEUS) To Your Watchlist Today?
May 26A Look At The Intrinsic Value Of Nucleus Software Exports Limited (NSE:NUCLEUS)
May 08Does Nucleus Software Exports (NSE:NUCLEUS) Have The Makings Of A Multi-Bagger?
Mar 05Are Strong Financial Prospects The Force That Is Driving The Momentum In Nucleus Software Exports Limited's NSE:NUCLEUS) Stock?
Feb 15I Ran A Stock Scan For Earnings Growth And Nucleus Software Exports (NSE:NUCLEUS) Passed With Ease
Jan 28Is Nucleus Software Exports Limited (NSE:NUCLEUS) Popular Amongst Insiders?
Jan 10Nucleus Software Exports (NSE:NUCLEUS) Has Gifted Shareholders With A Fantastic 135% Total Return On Their Investment
Dec 21Does Nucleus Software Exports Limited (NSE:NUCLEUS) Have A Place In Your Dividend Portfolio?
Dec 07Does Nucleus Software Exports (NSE:NUCLEUS) Have The Makings Of A Multi-Bagger?
Nov 22Nucleus Software Exports Limited's (NSE:NUCLEUS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Nov 09Here's Why I Think Nucleus Software Exports (NSE:NUCLEUS) Might Deserve Your Attention Today
Oct 27What Can We Make Of Nucleus Software Exports' (NSE:NUCLEUS) CEO Compensation?
Oct 14Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
3/31/2026 | 10,607 | 2,762 | 2,581 | 2,920 | 1 |
3/31/2025 | 9,174 | 2,265 | 2,305 | 2,604 | 1 |
3/31/2024 | 8,265 | 1,916 | 1,934 | 2,220 | N/A |
12/31/2023 | 8,224 | 2,071 | N/A | N/A | N/A |
9/30/2023 | 7,876 | 2,041 | 1,502 | 1,617 | N/A |
6/30/2023 | 7,124 | 1,706 | N/A | N/A | N/A |
3/31/2023 | 6,345 | 1,278 | 461 | 498 | N/A |
12/31/2022 | 5,813 | 784 | N/A | N/A | N/A |
9/30/2022 | 5,336 | 481 | 229 | 429 | N/A |
6/30/2022 | 5,176 | 457 | N/A | N/A | N/A |
3/31/2022 | 4,972 | 409 | 334 | 577 | N/A |
12/31/2021 | 4,683 | 500 | N/A | N/A | N/A |
9/30/2021 | 4,708 | 668 | 673 | 743 | N/A |
6/30/2021 | 4,936 | 876 | N/A | N/A | N/A |
3/31/2021 | 5,135 | 1,180 | 1,119 | 1,149 | N/A |
12/31/2020 | 5,276 | 1,187 | N/A | N/A | N/A |
9/30/2020 | 5,339 | 1,171 | 1,182 | 1,258 | N/A |
6/30/2020 | 5,251 | 1,088 | N/A | N/A | N/A |
3/31/2020 | 5,208 | 890 | 623 | 747 | N/A |
12/31/2019 | 5,096 | 779 | N/A | N/A | N/A |
9/30/2019 | 5,022 | 755 | 442 | 539 | N/A |
6/30/2019 | 4,955 | 735 | N/A | N/A | N/A |
3/31/2019 | 4,840 | 745 | 473 | 561 | N/A |
12/31/2018 | 4,681 | 747 | N/A | N/A | N/A |
9/30/2018 | 4,511 | 721 | N/A | N/A | N/A |
6/30/2018 | 4,301 | 686 | N/A | N/A | N/A |
3/31/2018 | 4,118 | 626 | 697 | 769 | N/A |
12/31/2017 | 3,945 | 622 | N/A | N/A | N/A |
9/30/2017 | 3,816 | 688 | N/A | N/A | N/A |
6/30/2017 | 3,768 | 652 | N/A | N/A | N/A |
3/31/2017 | 3,724 | 662 | N/A | 951 | N/A |
12/31/2016 | 3,714 | 599 | N/A | N/A | N/A |
9/30/2016 | 3,648 | 456 | N/A | N/A | N/A |
6/30/2016 | 3,538 | 365 | N/A | N/A | N/A |
3/31/2016 | 3,487 | 325 | N/A | 325 | N/A |
12/31/2015 | 3,569 | 390 | N/A | N/A | N/A |
9/30/2015 | 3,564 | 515 | N/A | N/A | N/A |
6/30/2015 | 3,585 | 599 | N/A | N/A | N/A |
3/31/2015 | 3,531 | 647 | N/A | 368 | N/A |
12/31/2014 | 3,399 | 629 | N/A | N/A | N/A |
9/30/2014 | 3,439 | 667 | N/A | N/A | N/A |
6/30/2014 | 3,393 | 648 | N/A | 458 | N/A |
3/31/2014 | 3,462 | 643 | N/A | 651 | N/A |
12/31/2013 | 3,320 | 559 | N/A | 617 | N/A |
9/30/2013 | 3,166 | 449 | N/A | 587 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: NUCLEUSDas prognostizierte Gewinnwachstum (18.1% pro Jahr) liegt über der Sparquote (6.7%).
Ertrag vs. Markt: NUCLEUSDie Erträge des Unternehmens (15.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (15.9% pro Jahr).
Hohe Wachstumserträge: NUCLEUSDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: NUCLEUSDie Einnahmen des Unternehmens (15.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.4% pro Jahr).
Hohe Wachstumseinnahmen: NUCLEUSDie Einnahmen des Unternehmens (15.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: NUCLEUSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (26.7%)